Skip to main content

Table 2 Traditional coagulation assessment at different time points

From: Does subcutaneous administration of recombinant human erythropoietin increase thrombotic events in total hip arthroplasty? A prospective thrombelastography analysis

Indexes

Time points

rHu-EPO group (n = 74)

Control group (n = 78)

P value

FDP (mg/l)

Pre-op

POD1

POD7

3.38 ± 1.16

13.34 ± 9.85

15.09 ± 3.97

3.47 ± 2.01

15.95 ± 14.00

16.16 ± 4.25

0.727

0.189

0.110

D-dimer(ng/ml)

Pre-op

POD1

POD7

1.18 ± 0.54

4.08 ± 1.75

4.77 ± 1.70

1.22 ± 0.74

4.47 ± 2.33

5.33 ± 2.42

0.710

0.241

0.105

PT(s)

Pre-op

POD1

POD7

11.64 ± 0.74

12.83 ± 1.14

12.24 ± 1.16

11.85 ± 0.95

13.05 ± 0.85

12.54 ± 1.06

0.141

0.163

0.099

APTT(s)

Pre-op

POD1

POD7

28.61 ± 3.34

31.80 ± 5.71

28.97 ± 3.41

28.81 ± 3.63

33.30 ± 5.48

30.02 ± 3.50

0.720

0.098

0.063

TT(s)

Pre-op

POD1

POD7

16.98 ± 0.93

15.86 ± 1.05

15.55 ± 0.77

17.24 ± 1.29

16.20 ± 1.22

15.79 ± 0.97

0.161

0.069

0.094

FIB(g/l)

Pre-op

POD1

POD7

3.52 ± 1.09

3.64 ± 1.01

4.82 ± 1.00

3.31 ± 0.95

3.84 ± 0.84

5.01 ± 1.03

0.204

0.176

0.268

INR

Pre-op

POD1

POD7

1.01 ± 0.08

1.13 ± 0.17

1.06 ± 0.10

1.03 ± 0.084

1.15 ± 0.11

1.09 ± 0.09

0.062

0.261

0.066

  1. *P < 0.05, Pre-op pre-operation, POD1 postoperative day 1, POD7 postoperative day 7, FDP fibrin degradation products, PT prothrombin time, APTT activated partial thromboplastin time, TT thrombin time, FIB fibrinogen, INR international normalized ratio